Abstract
<jats:p>Opioid receptors are groups of receptors (γ, κ-, δ- and ζ-opioid receptors) that are widely distributed in the nerve cells of the brain, the spinal cord and the digestive tract. Naltrexone is a type of general opioid receptor antagonist and has been used to treat chronic pain syndrome, autoimmune diseases, and cancer at a dose of 5 mg/day, which is often called Low Dose Naltrexone (LDN). This book analyzed the pharmacological functions of low-dose naltrexone, especially in anti-inflammation and immunoregulation, and its potential for immune-related diseases and cancer therapy. Low-dose naltrexone has immunomodulatory and therapeutic effects. Recent clinical studies have confirmed that low-dose naltrexone has played a significant role in the treatment and control of a variety of autoimmune diseases, for example, it prevents the recurrence and progression of multiple sclerosis, and low-dose naltrexone has been able to treat Crohn's disease. and mesentery panniculitis with little or no adverse reactions. Low-dose naltrexone regulates the production of inflammatory cytokines by influencing the level of endogenous opioid peptides in the body. Furthermore, low-dose naltrexone has an antitumor effect and can modulate the response of the neuroblastoma tumor, delaying the onset and reducing the incidence rate of tumors, significantly decreasing the volume and weight of the tumor and DNA synthesis in the tumor.</jats:p>